Immune-based Therapies in Cardiovascular and Metabolic Diseases: Past, Present and Future

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2021 Jul 21

PMID 34285393

Citations 15

Authors

Andrew J Murphy

Mark A Febbraio

Affiliations

Soon will be listed here.

Abstract

Cardiometabolic disorders were originally thought to be driven primarily by changes in lipid metabolism that cause the accumulation of lipids in organs, thereby impairing their function. Thus, in the setting of cardiovascular disease, statins - a class of lipid-lowering drugs - have remained the frontline therapy. In the past 20 years, seminal discoveries have revealed a central role of both the innate and adaptive immune system in driving cardiometabolic disorders. As such, it is now appreciated that immune-based interventions may have an important role in reducing death and disability from cardiometabolic disorders. However, to date, there have been a limited number of clinical trials exploring this interventional strategy. Nonetheless, elegant preclinical research suggests that immune-targeted therapies can have a major impact in treating cardiometabolic disease. Here, we discuss the history and recent advancements in the use of immunotherapies to treat cardiometabolic disorders.

Citing Articles

Lymphocyte Subset Imbalance in Cardiometabolic Diseases: Are T Cells the Missing Link?.

Picone F, Giudice V, Iside C, Venturini E, Di Pietro P, Vecchione C Int J Mol Sci. 2025; 26(3).

PMID: 39940640 PMC: 11816853. DOI: 10.3390/ijms26030868.

Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.

Khan A, Zakirullah , Wahab S, Hong S Virol J. 2025; 22(1):26.

PMID: 39905499 PMC: 11792744. DOI: 10.1186/s12985-025-02622-z.

Perspective: Pathological transdifferentiation-a novel therapeutic target for cardiovascular diseases and chronic inflammation.

Yang W, Ben Issa M, Saaoud F, Xu K, Shao Y, Lu Y Front Cardiovasc Med. 2024; 11:1500775.

PMID: 39660114 PMC: 11628510. DOI: 10.3389/fcvm.2024.1500775.

Immunometabolism in atherosclerotic disorders.

Fleetwood A, Noonan J, La Gruta N, Kallies A, Murphy A Nat Cardiovasc Res. 2024; 3(6):637-650.

PMID: 39196223 DOI: 10.1038/s44161-024-00473-5.

A Multi-Dimensional Approach to Map Disease Relationships Challenges Classical Disease Views.

Mobus L, Serra A, Fratello M, Pavel A, Federico A, Greco D Adv Sci (Weinh). 2024; 11(30):e2401754.

PMID: 38840452 PMC: 11321629. DOI: 10.1002/advs.202401754.

References

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

Pearson T, Blair S, Daniels S, Eckel R, Fair J, Fortmann S . AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association.... Circulation. 2002; 106(3):388-91. DOI: 10.1161/01.cir.0000020190.45892.75. View

Greenland P, Alpert J, Beller G, Benjamin E, Budoff M, Fayad Z . 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010; 122(25):e584-636. DOI: 10.1161/CIR.0b013e3182051b4c. View

Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140(11):e596-e646. PMC: 7734661. DOI: 10.1161/CIR.0000000000000678. View

Wolf D, Ley K . Immunity and Inflammation in Atherosclerosis. Circ Res. 2019; 124(2):315-327. PMC: 6342482. DOI: 10.1161/CIRCRESAHA.118.313591. View

Hotamisligil G, Shargill N, Spiegelman B . Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87-91. DOI: 10.1126/science.7678183. View

Kubota T, McTiernan C, FRYE C, Slawson S, Lemster B, Koretsky A . Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997; 81(4):627-35. DOI: 10.1161/01.res.81.4.627. View

Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H . Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun. 2001; 289(4):901-7. DOI: 10.1006/bbrc.2001.6068. View

Bradham W, Bozkurt B, Gunasinghe H, Mann D, Spinale F . Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002; 53(4):822-30. DOI: 10.1016/s0008-6363(01)00503-x. View

10.

Bozkurt B, Torre-Amione G, Warren M, Whitmore J, Soran O, Feldman A . Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001; 103(8):1044-7. DOI: 10.1161/01.cir.103.8.1044. View

11.

Chung E, Packer M, Lo K, Fasanmade A, Willerson J . Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart.... Circulation. 2003; 107(25):3133-40. DOI: 10.1161/01.CIR.0000077913.60364.D2. View

12.

Esser N, Paquot N, Scheen A . Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2014; 24(3):283-307. DOI: 10.1517/13543784.2015.974804. View

13.

Bernstein L, Berry J, Kim S, Canavan B, Grinspoon S . Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006; 166(8):902-8. PMC: 3196549. DOI: 10.1001/archinte.166.8.902. View

14.

Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S . Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24(11):2137-42. DOI: 10.1161/01.ATV.0000143933.20616.1b. View

15.

Xanthoulea S, Thelen M, Pottgens C, Gijbels M, Lutgens E, de Winther M . Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. PLoS One. 2009; 4(7):e6113. PMC: 2702081. DOI: 10.1371/journal.pone.0006113. View

16.

Dinarello C, Renfer L, Wolff S . Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A. 1977; 74(10):4624-7. PMC: 431999. DOI: 10.1073/pnas.74.10.4624. View

17.

Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M . Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996; 97(3):769-76. PMC: 507115. DOI: 10.1172/JCI118476. View

18.

Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y . Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23(4):656-60. DOI: 10.1161/01.ATV.0000064374.15232.C3. View

19.

Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

20.

Ridker P, Everett B, Pradhan A, MacFadyen J, Solomon D, Zaharris E . Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2018; 380(8):752-762. PMC: 6587584. DOI: 10.1056/NEJMoa1809798. View